Terms: = Prostate cancer AND PTEN, MMAC1, 5728, MGC11227, PTEN1, MHAM, P60484, BZS, ENSG00000171862 AND Clinical Outcome
33 results:
1. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
2. Glycyl-tRNA Synthetase (GARS) Expression Is Associated with prostate cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.
Khosh Kish E; Gamallat Y; Choudhry M; Ghosh S; Seyedi S; Bismar TA
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901698
[TBL] [Abstract] [Full Text] [Related]
3. The Association between Cyclin Dependent Kinase 2 Associated Protein 1 (CDK2AP1) and Molecular Subtypes of Lethal prostate cancer.
Gamallat Y; Bakker A; Khosh Kish E; Choudhry M; Walker S; Aldakheel S; Seyedi S; Huang KC; Ghosh S; Gotto G; Bismar TA
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362115
[TBL] [Abstract] [Full Text] [Related]
4. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with pten loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
5. Non-canonical EphA2 activation underpins pten-mediated metastatic migration and poor clinical outcome in prostate cancer.
Sachdeva A; Hart CA; Kim K; Tawadros T; Oliveira P; Shanks J; Brown M; Clarke N
Br J Cancer; 2022 Oct; 127(7):1254-1262. PubMed ID: 35869144
[TBL] [Abstract] [Full Text] [Related]
6. The pten Conundrum: How to Target pten-Deficient prostate cancer.
Turnham DJ; Bullock N; Dass MS; Staffurth JN; Pearson HB
Cells; 2020 Oct; 9(11):. PubMed ID: 33105713
[TBL] [Abstract] [Full Text] [Related]
7. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
[TBL] [Abstract] [Full Text] [Related]
8. BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration.
Loveridge CJ; Slater S; Campbell KJ; Nam NA; Knight J; Ahmad I; Hedley A; Lilla S; Repiscak P; Patel R; Salji M; Fleming J; Mitchell L; Nixon C; Strathdee D; Neilson M; Ntala C; Bryson S; Zanivan S; Edwards J; Robson CN; Goodyear CS; Blyth K; Leung HY
Oncogene; 2020 Feb; 39(8):1797-1806. PubMed ID: 31740786
[TBL] [Abstract] [Full Text] [Related]
9. Combined loss of TFF3 and pten is associated with lethal outcome and overall survival in men with prostate cancer.
Abou-Ouf H; Ghosh S; Box A; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1751-1759. PubMed ID: 31129769
[TBL] [Abstract] [Full Text] [Related]
10. Chromatin remodeling ATPase BRG1 and pten are synthetic lethal in prostate cancer.
Ding Y; Li N; Dong B; Guo W; Wei H; Chen Q; Yuan H; Han Y; Chang H; Kan S; Wang X; Pan Q; Wu P; Peng C; Qiu T; Li Q; Gao D; Xue W; Qin J
J Clin Invest; 2019 Feb; 129(2):759-773. PubMed ID: 30496141
[TBL] [Abstract] [Full Text] [Related]
11. clinical utility of assessing pten and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
[TBL] [Abstract] [Full Text] [Related]
12. A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.
Zhong Q; Guo T; Rechsteiner M; Rüschoff JH; Rupp N; Fankhauser C; Saba K; Mortezavi A; Poyet C; Hermanns T; Zhu Y; Moch H; Aebersold R; Wild PJ
Sci Data; 2017 Mar; 4():170014. PubMed ID: 28291248
[TBL] [Abstract] [Full Text] [Related]
13. SPINK1 Overexpression in Localized prostate cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous pten Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract] [Full Text] [Related]
14. DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.
Liu W
Asian J Androl; 2016; 18(4):533-42. PubMed ID: 26975494
[TBL] [Abstract] [Full Text] [Related]
15. [The mechanism of progression without androgen receptor interaction in prostate cancer].
Matsuyama H; Matsumoto H
Nihon Rinsho; 2016 Jan; 74(1):60-5. PubMed ID: 26793881
[TBL] [Abstract] [Full Text] [Related]
16. Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal prostate cancer.
Mehra R; Udager AM; Ahearn TU; Cao X; Feng FY; Loda M; Petimar JS; Kantoff P; Mucci LA; Chinnaiyan AM
Eur Urol; 2016 Oct; 70(4):549-552. PubMed ID: 26724257
[TBL] [Abstract] [Full Text] [Related]
17. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.
Ross-Adams H; Lamb AD; Dunning MJ; Halim S; Lindberg J; Massie CM; Egevad LA; Russell R; Ramos-Montoya A; Vowler SL; Sharma NL; Kay J; Whitaker H; Clark J; Hurst R; Gnanapragasam VJ; Shah NC; Warren AY; Cooper CS; Lynch AG; Stark R; Mills IG; Grönberg H; Neal DE;
EBioMedicine; 2015 Sep; 2(9):1133-44. PubMed ID: 26501111
[TBL] [Abstract] [Full Text] [Related]
18. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
[TBL] [Abstract] [Full Text] [Related]
19. pten Loss Is Associated with Worse outcome in HER2-Amplified Breast cancer Patients but Is Not Associated with Trastuzumab Resistance.
Stern HM; Gardner H; Burzykowski T; Elatre W; O'Brien C; Lackner MR; Pestano GA; Santiago A; Villalobos I; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Nuciforo P; Bee V; Mackey J; Slamon DJ; Press MF
Clin Cancer Res; 2015 May; 21(9):2065-74. PubMed ID: 25649019
[TBL] [Abstract] [Full Text] [Related]
20. pten protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Ferraldeschi R; Nava Rodrigues D; Riisnaes R; Miranda S; Figueiredo I; Rescigno P; Ravi P; Pezaro C; Omlin A; Lorente D; Zafeiriou Z; Mateo J; Altavilla A; Sideris S; Bianchini D; Grist E; Thway K; Perez Lopez R; Tunariu N; Parker C; Dearnaley D; Reid A; Attard G; de Bono J
Eur Urol; 2015 Apr; 67(4):795-802. PubMed ID: 25454616
[TBL] [Abstract] [Full Text] [Related]
[Next]